Geron Stock

Geron Net Debt per Share

The Net Debt per Share of Geron (GERN) as of Aug 22, 2026 is -0.33 USD. In the previous year, Net Debt per Share was -0.26 USD — a change of 29.38% (lower).

Net Debt per Share

-0.33USD

YoY

29.38%

Last updated:

Net Debt per Share of Geron is 2026 -0.33 USD. Net Debt per Share of Geron was 2025 -0.26 USD. It decreases by 29.38% lower compared to the previous year.

The Geron Net Debt per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Debt per Share
Date
Net Debt per Share
Jan 1, 2017
-0.15 USD
Jan 1, 2018
-0.26 USD
Jan 1, 2019
-0.22 USD
Jan 1, 2020
-0.27 USD
Jan 1, 2021
-0.21 USD
Jan 1, 2022
-0.19 USD
Jan 1, 2023
-0.39 USD
Jan 1, 2024
-0.26 USD
The Geron Net Debt per Share history
YEARNet Debt per ShareYoY
-0.26USD-35.14%
-0.39USD+107.13%
-0.19USD-9.24%
-0.21USD-22.26%
-0.27USD+23.65%
-0.22USD-14.82%
-0.26USD+72.25%
-0.15USD-17.51%
-0.18USD+0.94%
-0.18USD-24.83%
-0.24USD
Access this data via the Eulerpool API

Geron Stock analysis

What does Geron do? Geron Corp is a biopharmaceutical company headquartered in Menlo Park, California, founded in 1990. The company's goal is to develop innovative products and therapies that have the potential to combat serious diseases. Geron Corp specializes in the research of embryonic stem cells. The company is a pioneer in researching technologies for the use of stem cells and has made significant breakthroughs in the field of regenerative medicine. By developing new stem cell therapies, Geron Corp aims to improve the lives of patients with serious conditions such as cancer, Parkinson's disease, and spinal cord injuries. Geron Corp operates various business segments, including oncology, regenerative medicine, and RNA-based therapies. In the field of oncology, the company focuses on developing therapies for the treatment of cancer, particularly solid tumors. One of the most important developments is the drug Imetelstat, which aims to extend the telomeres of cancer cells by inhibiting the activity of telomerase. Imetelstat is currently in various clinical trials and has the potential to revolutionize the treatment of leukemia and other types of cancer. Another important business segment of Geron Corp is regenerative medicine, particularly the research of therapies for repairing spinal cord injuries. The company has made significant breakthroughs in this area and has a promising pipeline of products aimed at repairing damaged nerve cells in the spinal cord and restoring patients' mobility. Geron Corp is also a leading company in the field of RNA-based therapies. RNA-based therapies aim to regulate gene activity to treat diseases. The company has developed various innovative technologies aimed at accelerating and enhancing the development of RNA-based therapies. In recent years, Geron Corp has brought a variety of products to the market, including drugs for the treatment of spinal cord injuries, leukemia, and other types of cancer. The company has also formed partnerships with other leading companies in the biopharmaceutical industry to advance the development and commercialization of products. Overall, Geron Corp has made a significant contribution to the research and development of new technologies and therapies with the potential to improve the lives of millions of people. The company has a promising pipeline of products and is committed to further solidifying its position as a leading company in the biopharmaceutical industry. Geron is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Geron stock

Net Debt per Share of Geron is -0.33 USD in 2026.

Net Debt per Share of Geron changed from -0.26 USD to -0.33 USD, representing a 29.38% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Net Debt per Share Geron since 2006 – with annual values, charts, and detailed analysis.

Net debt per share divides net debt by shares outstanding, showing the debt burden attributable to each share after accounting for cash reserves.

Access this data via the Eulerpool API

Other — Geron

All Key Metrics — Geron